# Akebia Therapeutics (AKBA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AKBA
## Company Profile
- Ticker: AKBA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.8932 USD
- Market cap: 251197018.7452 USD
- Last updated: 2026-08-12
## Business Overview
### Kidney-Disease Company
Akebia Therapeutics develops and commercializes medicines for people with kidney disease. Its portfolio combines an anemia franchise with clinical programs for rare and acute renal disorders.
### Vafseo
Vafseo, or vadadustat, is an oral HIF prolyl-hydroxylase inhibitor for anemia due to chronic kidney disease in adults receiving dialysis. Akebia is conducting post-approval studies of alternative dosing and clinical outcomes.
### Vafseo Evidence Program
The VOCAL Phase 3b study evaluates three-times-weekly Vafseo dosing, while the large Phase 4 VOICE study compares mortality and hospitalization outcomes with standard erythropoiesis-stimulating agents.
### Praliciguat
Praliciguat is an oral soluble-guanylate-cyclase stimulator in Phase 2 testing for focal segmental glomerulosclerosis.
### AKB-097
AKB-097 is preparing for a Phase 2 basket study in IgA nephropathy, lupus nephritis and C3 glomerulopathy.
### AKB-9090
AKB-9090 is in Phase 1 development as a potential preventive treatment for cardiac-surgery-associated acute kidney injury.
## Why The Stock Is Moving

As of Aug 12, 2026, AKBA closed up 3.08% at $0.8932. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of a Phase 2 basket study of AKB-097 in the second half of 2026.
- Topline Phase 3b VOCAL data in the fourth quarter of 2026.
- Topline Phase 1 data for AKB-9090 in early 2027.
- Initial Phase 2 data for AKB-097 in 2027.
- Topline Phase 4 VOICE data in early 2027.

## Recent News
- 2026-08-05 20:05 EST — [Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-second-quarter-2026-financial-results-and-business-h-372d5580) — Source: Akebia Therapeutics
- 2026-08-03 12:00 EST — [Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-announces-initiation-of-a-phase-2-basket-trial-to-study-ebri-eb84a9e4) — Source: Akebia Therapeutics
- 2026-07-29 12:00 EST — [Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-report-second-quarter-2026-financial-results-and-discuss--2657d229) — Source: Akebia Therapeutics
- 2026-07-02 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc8c2359) — Source: Akebia Therapeutics
- 2026-06-30 12:00 EST — [U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA](https://biopharmsignal.com/news/AKBA/u-s-renal-care-and-akebia-announce-interim-analysis-of-voice-trial-demonstrated--7cc9c9bc) — Source: Akebia Therapeutics